6HN.F EVEREST MED.LTD DL-0001

Healthcare Biotechnology Frankfurt Exchange
2.98 EUR
Close of Nov 11, 2026
2.48 5.30
Market cap
EUR 1.05B
P/E
-
P/B
1.51x
ROE
-5.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6HN.F undervalued?

Graham number

The Graham number of EVEREST MED.LTD DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EVEREST MED.LTD DL-0001 fundamental analysis

No fundamental analysis for EVEREST MED.LTD DL-0001 yet.

EVEREST MED.LTD DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EVEREST MED.LTD DL-0001

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptibl…

Full company profile